EA201890570A1 - [4-(1,3,3-триметил-2-оксо-3,4-дигидро-1h-хиноксалин-7-ил)фенокси]этилокси соединение или его соль - Google Patents
[4-(1,3,3-триметил-2-оксо-3,4-дигидро-1h-хиноксалин-7-ил)фенокси]этилокси соединение или его сольInfo
- Publication number
- EA201890570A1 EA201890570A1 EA201890570A EA201890570A EA201890570A1 EA 201890570 A1 EA201890570 A1 EA 201890570A1 EA 201890570 A EA201890570 A EA 201890570A EA 201890570 A EA201890570 A EA 201890570A EA 201890570 A1 EA201890570 A1 EA 201890570A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- salt
- trimethyl
- oxo
- digidro
- penoxy
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title abstract 3
- -1 ETHYLOXY COMPOUND Chemical class 0.000 title abstract 2
- 102000003676 Glucocorticoid Receptors Human genes 0.000 abstract 2
- 108090000079 Glucocorticoid Receptors Proteins 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 230000001270 agonistic effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6509—Six-membered rings
- C07F9/650952—Six-membered rings having the nitrogen atoms in the positions 1 and 4
- C07F9/650994—Six-membered rings having the nitrogen atoms in the positions 1 and 4 condensed with carbocyclic rings or carbocyclic ring systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015166247 | 2015-08-25 | ||
| PCT/JP2016/074863 WO2017034006A1 (ja) | 2015-08-25 | 2016-08-25 | ［４－（１，３，３－トリメチル－２－オキソ－３，４－ジヒドロ－１ｈ－キノキサリン－７－イル）フェノキシ］エチルオキシ化合物またはその塩 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201890570A1 true EA201890570A1 (ru) | 2018-08-31 |
Family
ID=58100493
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201890570A EA201890570A1 (ru) | 2015-08-25 | 2016-08-25 | [4-(1,3,3-триметил-2-оксо-3,4-дигидро-1h-хиноксалин-7-ил)фенокси]этилокси соединение или его соль |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US10189796B2 (enExample) |
| EP (1) | EP3342768A4 (enExample) |
| JP (2) | JP2017043614A (enExample) |
| KR (1) | KR20180043329A (enExample) |
| CN (1) | CN107922356A (enExample) |
| CA (1) | CA2996278A1 (enExample) |
| EA (1) | EA201890570A1 (enExample) |
| HK (1) | HK1252159A1 (enExample) |
| WO (1) | WO2017034006A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HK1252159A1 (zh) * | 2015-08-25 | 2019-05-17 | 参天制药株式会社 | [4-(1，3，3-三甲基-2-氧代-3，4-二氢-1h-喹喔啉-7-基)苯氧基]乙基氧基化合物或其盐 |
| WO2018230713A1 (ja) | 2017-06-16 | 2018-12-20 | 学校法人同志社 | カスパーゼ阻害活性を有する化合物、これらの化合物を含む、角膜内皮の症状、障害または疾患を治療または予防するための医薬およびその応用 |
| EP3639854B1 (en) | 2017-06-16 | 2026-01-07 | The Doshisha | Mtor-inhibitor-containing medicine for treating or preventing fuchs' endothelial corneal dystrophy |
| CA3085874A1 (en) | 2017-12-18 | 2019-06-27 | Grunenthal Gmbh | Substituted pyrrolidine amides i |
| TW201927769A (zh) | 2017-12-18 | 2019-07-16 | 德商歌林達有限公司 | 經取代之吡咯啶醯胺ｉｉ |
| AR117951A1 (es) | 2018-07-20 | 2021-09-08 | Gruenenthal Gmbh | Derivados de triazolquinoxalina adicionalmente sustituidos |
| HRP20221020T1 (hr) | 2018-07-20 | 2022-11-11 | Grünenthal GmbH | Supstituirani derivati triazolo kinoksalina |
| WO2020144375A1 (en) | 2019-01-11 | 2020-07-16 | Grünenthal GmbH | Substituted pyrrolidine amides iii |
| EP3986885B1 (en) | 2019-06-19 | 2023-05-03 | Grünenthal GmbH | Substituted pyrrolidine amides iv |
| EP3986886A2 (en) | 2019-06-19 | 2022-04-27 | Grünenthal GmbH | Substituted pyrrolidine amides v |
| WO2021144440A1 (en) | 2020-01-17 | 2021-07-22 | Grünenthal GmbH | Quinoxaline derivatives as modulators of the glucocorticoid receptor |
| ES2976780T3 (es) | 2020-01-17 | 2024-08-08 | Gruenenthal Gmbh | Derivados de quinoxalina |
| ES3057363T3 (en) | 2020-07-09 | 2026-03-02 | Gruenenthal Gmbh | Substituted pyrrolidine amines and amides as mediator of the glucocortoid receptor |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2246292T3 (es) | 2000-10-30 | 2006-02-16 | Pfizer Products Inc. | Moduladores de receptor glucocorticoide. |
| JP5054996B2 (ja) * | 2006-03-14 | 2012-10-24 | 参天製薬株式会社 | グルココルチコイド受容体結合活性を有する新規１，２，３，４−テトラヒドロキノキサリン誘導体 |
| CN101400659B (zh) * | 2006-03-14 | 2012-02-29 | 参天制药株式会社 | 具有糖皮质激素受体结合活性的新型1，2，3，4-四氢喹喔啉衍生物 |
| EP2151436B1 (en) * | 2007-05-29 | 2013-04-24 | Santen Pharmaceutical Co., Ltd | Novel 1,2,3,4-tetrahydroquinoxaline derivative which has, as substituent, phenyl group having sulfonic acid ester structure or sulfonic acid amide structure introduced therein and has glucocorticoid receptor-binding activity |
| JP2009084273A (ja) * | 2007-09-13 | 2009-04-23 | Santen Pharmaceut Co Ltd | １，３，３−トリメチル−７−フェニル−３，４−ジヒドロ−１ｈ−キノキサリン−２−オン誘導体からなるグルココルチコイド受容体アゴニスト |
| WO2009035068A1 (ja) * | 2007-09-13 | 2009-03-19 | Santen Pharmaceutical Co., Ltd. | 新規１，３，３－トリメチル－７－フェニル－３，４－ジヒドロ－１ｈ－キノキサリン－２－オン誘導体 |
| TWI510240B (zh) | 2008-05-12 | 2015-12-01 | 由具有取代氧基之２，２，４－三甲基－６－苯基－１，２－二氫喹啉衍生物組成之糖皮質激素受體激動劑 | |
| GEP20135804B (en) * | 2008-09-12 | 2013-04-10 | Santen Pharmaceutical Co Ltd | Glucocorticoid receptor agonist comprising novel 1,2,3,4-tetrahydroquinoxaline derivative containing phenyl group having sulfonic acid ester introduced therein as substituent |
| HK1252159A1 (zh) * | 2015-08-25 | 2019-05-17 | 参天制药株式会社 | [4-(1，3，3-三甲基-2-氧代-3，4-二氢-1h-喹喔啉-7-基)苯氧基]乙基氧基化合物或其盐 |
-
2016
- 2016-08-25 HK HK18111552.7A patent/HK1252159A1/zh unknown
- 2016-08-25 KR KR1020187008105A patent/KR20180043329A/ko not_active Ceased
- 2016-08-25 JP JP2016164830A patent/JP2017043614A/ja active Pending
- 2016-08-25 US US15/753,410 patent/US10189796B2/en active Active
- 2016-08-25 CN CN201680049254.XA patent/CN107922356A/zh active Pending
- 2016-08-25 EA EA201890570A patent/EA201890570A1/ru unknown
- 2016-08-25 EP EP16839353.6A patent/EP3342768A4/en not_active Withdrawn
- 2016-08-25 CA CA2996278A patent/CA2996278A1/en not_active Abandoned
- 2016-08-25 WO PCT/JP2016/074863 patent/WO2017034006A1/ja not_active Ceased
-
2018
- 2018-12-05 US US16/210,163 patent/US10435379B2/en not_active Expired - Fee Related
-
2019
- 2019-08-06 US US16/532,533 patent/US20190359577A1/en not_active Abandoned
-
2021
- 2021-05-28 JP JP2021089664A patent/JP7037687B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20180244633A1 (en) | 2018-08-30 |
| US10435379B2 (en) | 2019-10-08 |
| EP3342768A1 (en) | 2018-07-04 |
| HK1252159A1 (zh) | 2019-05-17 |
| US20190359577A1 (en) | 2019-11-28 |
| CN107922356A (zh) | 2018-04-17 |
| JP2017043614A (ja) | 2017-03-02 |
| US10189796B2 (en) | 2019-01-29 |
| JP2021138728A (ja) | 2021-09-16 |
| US20190106393A1 (en) | 2019-04-11 |
| WO2017034006A1 (ja) | 2017-03-02 |
| KR20180043329A (ko) | 2018-04-27 |
| EP3342768A4 (en) | 2019-01-23 |
| JP7037687B2 (ja) | 2022-03-16 |
| CA2996278A1 (en) | 2017-03-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018015625A (es) | Compuestos y composiciones para inhibir la actividad de shp2. | |
| EA201692301A1 (ru) | Производные бороновой кислоты и их терапевтическое применение | |
| MX391850B (es) | Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington | |
| SG11201806930PA (en) | Novel condensed pyrimidine compound or salt thereof | |
| BR112018006866A2 (pt) | compostos agonistas de ppar, composições farmacêuticas e métodos de uso dos mesmos | |
| TN2016000268A1 (en) | N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of shp2. | |
| EA201591745A1 (ru) | 3-пиримидин-4-ил-оксазолидин-2-оны в качестве ингибиторов мутантого idh | |
| NZ724878A (en) | Compounds and compositions as toll-like receptor 7 agonists | |
| NZ724792A (en) | Compounds and compositions as toll-like receptor 7 agonists | |
| EA201591727A1 (ru) | Соединения биариламида в качестве ингибиторов киназы | |
| EA201690629A1 (ru) | Соединения, которые представляют собой тройные агонисты, глюкагона, glp-1 и gip | |
| EA201400161A1 (ru) | Замещенные гетероароматические пиразолсодержащие карбоксамидные и мочевинные производные в качестве лигандов ваниллоидных рецепторов | |
| EA201501142A1 (ru) | Гетероциклические соединения в качестве средств для борьбы с вредителями | |
| CL2016002072A1 (es) | 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer | |
| PH12017501095A1 (en) | Piperidine derivatives as hdac1/2 inhibitors | |
| MX373549B (es) | Derivado de pirazol amida. | |
| PH12017500401A1 (en) | Therapeutic compounds as inhibitors of the orexin-1 receptor | |
| EA201590562A1 (ru) | Бензамиды | |
| PL410665A1 (pl) | Inhibitory arginazy oraz ich zastosowania terapeutyczne | |
| WO2016004404A3 (en) | Gls1 inhibitors for treating disease | |
| JOP20200100A1 (ar) | مشتقات بيرازولو-بيرولو-بيريميدين-ديون جديدة كمثبِّطات لـ p2x3 | |
| EA201890449A1 (ru) | Фумагиллиновые гетероциклические соединения и способы их получения и применения | |
| EA201692481A1 (ru) | Комбинация, содержащая глюкокортикоид и edo-s101 | |
| MY201535A (en) | Therapeutic compounds | |
| BR112016028037A2 (pt) | Novos compostos |